News
Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...
If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi ...
12h
Health on MSNThis New Pill Could Rival Ozempic and Wegovy—Will It Make Weight Loss Drugs More Accessible?Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...
HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.
19h
Pharmaceutical Technology on MSNNovo Nordisk’s CEO to step down as weight loss market share plummetsNovo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...
The price of Wegovy, Novo Nordisk’s blockbuster weight-loss drug, is $1,349 a month in the U.S.; in Germany, it’s $328. The U.S. price for Keytruda, a cancer treatment, is $191,000 ...
Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results